Patrick W. Smith Sells 4,767 Shares of Axon Enterprise, Inc. (NASDAQ:AXON) Stock

Axon Enterprise, Inc. (NASDAQ:AXON) CEO Patrick W. Smith sold 4,767 shares of Axon Enterprise stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $404.14, for a total transaction of $1,926,535.38. Following the completion of the transaction, the chief executive officer now directly owns 2,925,060 shares in the company, valued at approximately $1,182,133,748.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $421.80 on Friday. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a 12 month low of $192.63 and a 12 month high of $422.33. The company has a 50 day simple moving average of $365.66 and a two-hundred day simple moving average of $323.47. The stock has a market cap of $31.83 billion, a price-to-earnings ratio of 123.33, a PEG ratio of 10.84 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The business had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same period in the previous year, the business posted $0.80 EPS. The business’s quarterly revenue was up 34.5% compared to the same quarter last year. As a group, analysts predict that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Hedge Funds Weigh In On Axon Enterprise

Large investors have recently made changes to their positions in the company. Avantax Advisory Services Inc. lifted its stake in shares of Axon Enterprise by 0.8% in the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after purchasing an additional 40 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Axon Enterprise in the 1st quarter valued at $931,000. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of Axon Enterprise by 14.8% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock valued at $53,307,000 after purchasing an additional 22,013 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Axon Enterprise by 21.7% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock valued at $2,693,000 after purchasing an additional 1,634 shares during the period. Finally, Cim LLC acquired a new position in shares of Axon Enterprise in the 4th quarter valued at $1,409,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on AXON. JMP Securities lifted their price objective on shares of Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Robert W. Baird lifted their target price on shares of Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Bank of America initiated coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $380.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $400.00 target price on shares of Axon Enterprise in a research note on Wednesday, August 7th. Finally, Barclays lifted their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $365.38.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.